Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patients
Sight Sciences announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophakic glaucoma patients with a history of trabecular microbypass stent implantation (iStent or iStent Inject) whose pressure is no longer controlled by the bypass stent and IOP-lowering medications.
“Glaucoma is a chronic disease, and most patients will need a variety of treatments over the course of their lives. Compliance with daily glaucoma medications can be low, and depending on the patient and stage of disease progression, some interventions such as bypass stents and/or IOP-lowering medications may run their natural course and no longer control the disease,” Deepan Selvadurai, MD, a glaucoma specialist and cataract surgeon at Buffalo Ophthalmology in Buffalo, New York, and a clinical investigator and co-author of the study, said in a company news release. “The OMNI Surgical System offers a potent implant-free procedure that I have found to be effective and durable in my pseudophakic patients where I had previously implanted trabecular bypass stents at the time of cataract surgery. This study showed that canaloplasty followed by trabeculotomy with OMNI as a standalone procedure in pseudophakic eyes with stents was highly effective in reducing IOP.”
The OMNI Surgical System is an implant-free procedure that addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm’s canal, and the collector channels. Because it offers a comprehensive mechanism of action through sequential canaloplasty and trabeculotomy, OMNI surgeons can successfully intervene in the same conventional outflow pathway anatomy when trabecular bypass implants and medications are no longer able to control IOP.
“More than one million eyes have received trabecular microbypass stent implants. Over time, these patients may progress to the point where their IOP is no longer adequately controlled by the implant and/or IOP-lowering medications,” said Paul Badawi, CEO and co-founder of Sight Sciences. “Substantial data supports OMNI’s effectiveness in combination with cataract surgery as well as its standalone use. This important multicenter data shows that OMNI can also help our customers address this large, existing, and growing subset of pseudophakic stented glaucoma patients. We view this as additional validation that OMNI has the unique potential to provide benefit throughout the entire life cycle of glaucoma disease–performed before, during, and after cataract surgery.”
Authors and affiliations: Daniel C. Terveen MD, Adam R. Bleeker MD of Vance Thompson Vision, Steven R. Sarkisian Jr., MD of Oklahoma Eye Surgeons, Steven D. Vold MD of Vold Vision, Deepan Selvadurai MD of Buffalo Ophthalmology, Blake K. Williamson MD, The Williamson Eye Center, Deborah G. Ristvedt MD of Vance Thompson Vision, Kavita Dhamdhere Phd of Sight Sciences and Mahatma Gandhi Medical College, Jaime E. Dickerson Jr., PhD, of Sight Sciences and North Texas Eye Research Institute.
Paper Reference: Terveen, D.C., Sarkisian, S.R., Vold, S.D. et al. Canaloplasty and trabeculotomy with the OMNI® surgical system in OAG with prior trabecular microbypass stenting. Int Ophthalmol (2022). https://doi.org/10.1007/s10792-022-02553-6
iStent and iStent Inject are registered trademarks of Glaukos Corporation.